Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Catechol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.83 |
| ▸ | CA2 | P00918 | 6/20 | 0.83 |
| ▸ | HPGD | P15428 | 4/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.83 |
| ▸ | CA4 | P22748 | 4/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | CA12 | O43570 | 3/20 | 0.83 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.83 |
| ▸ | EGFR | P00533 | 2/20 | 0.83 |
| ▸ | FYN | P06241 | 2/20 | 0.83 |
| ▸ | MMP9 | P14780 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | NPC1 | O15118 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | CA3 | P07451 | 2/20 | 0.83 |
| ▸ | GMNN | O75496 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Catechol SCHEMBL2388352 | 0.96 | ALDH1A1 (0.91) | ALDH1A1CA2HPGDTDP1CA4 | |
| Catechol SCHEMBL186880 | 0.96 | — | — | |
| Catechol SCHEMBL27577771 | 0.96 | — | — | |
| Catechol SCHEMBL9187087 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2HPGDTDP1CA4 | |
| Catechol SCHEMBL11319346 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2HPGDTDP1CA4 | |
| Catechol SCHEMBL11041074 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2HPGDTDP1CA4 | |
| Catechol SCHEMBL5114660 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2HPGDTDP1CA4 | |
| Catechol SCHEMBL30944695 | 0.91 | ALDH1A1 (1.00) | ALDH1A1CA2HPGDTDP1CA4 | |
| Catechol SCHEMBL30088487 | 0.91 | — | — | |
| Catechol SCHEMBL367675 | 0.91 | ALDH1A1 (1.00) | ALDH1A1CA2HPGDTDP1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009437-A1 | A CATECHOLAMINE DERIVATIVE USEFUL FOR THE TREATMENT OF PARKINSON'S DISEASE | H. Lundbeck A/S (DK) | 2016-04-20 | — | — | EP | disclosed |
| EP-2197883-B1 | Catecholamine derivative useful for the treatment of parkinson's disease | LUNDBECK & CO AS H (DK) | 2015-11-18 | — | — | EP | disclosed |
| EP-2662358-A1 | Catecholamine derivatives and prodrugs thereof | H. Lundbeck A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| EP-2197883-A1 | CATECHOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF PARKINSON' S DISEASE | H. Lundbeck A/S (DK) | 2010-06-23 | — | — | EP | disclosed |
| EP-2195291-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. Lundbeck A/S (DK) | 2010-06-16 | — | — | EP | disclosed |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| WO-2009026934-A1 | CATECHOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF PARKINSON' S DISEASE | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026935-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | ALDH1A1 287/4885CA2 2166/4885HPGD 187/4885 |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | ALDH1A1 287/4885CA2 2166/4885HPGD 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.